Hormone Receptor, HER2/NEU and EGFR Expression in Ovarian Carcinoma - is here a Prognostic Phenotype? |
Demir, Lutfiye
(Department of Medical Oncology, Ataturk State Hospital)
Yigit, Seyran (Department of Pathology, Ataturk Training and Research Hospital, Katip Celebi University) Sadullahoglu, Canan (Department of Pathology, Ege University) Akyol, Murat (Department of Medical Oncology, Ataturk Training and Research Hospital, Katip Celebi University) Cokmert, Suna (Department of Basic Oncology, Institute of Oncology, Dokuz Eylul University) Kucukzeybek, Yuksel (Department of Medical Oncology, Ataturk Training and Research Hospital, Katip Celebi University) Alacacioglu, Ahmet (Department of Medical Oncology, Ataturk Training and Research Hospital, Katip Celebi University) Cakalagaoglu, Fulya (Department of Pathology, Ataturk Training and Research Hospital, Katip Celebi University) Tarhan, Mustafa Oktay (Department of Preventive Oncology, Institute of Oncology, Dokuz Eylul University) |
1 | Boente MP, Chi DS, Hoskins WJ (1998). The role of surgery in the management of ovarian cancer: primary and interval cytoreductive surgery. Semin Oncol, 25, 326. |
2 | Bodnar L, Stanczak A, Cierniak S, et al (2014). Wnt/-catenin pathway as a potential prognostic and predictive marker in patients with advanced ovarian cancer. J Ovarian Res, 7, 16. DOI |
3 | Bookman MA, Darcy KM, Clarke-Pearson D, Boothby RA, Horowitz IR (2003). Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol, 21, 283-90. DOI ScienceOn |
4 | Bosmuller H, Haitchi-Petnehazy S, Webersinke G, et al (2011). Intratumoral lymphocyte density in serous ovarian carcinoma is superior to ERCC1 expression for predicting response to platinum-based therapy. Virchows Arch, 459, 183-91. DOI |
5 | Chumworathayi B (2013) Personalized cancer treatment for ovarian cancer. Asian Pac J Cancer Prev, 14, 1661-4. 과학기술학회마을 DOI ScienceOn |
6 | Crawford SC, Vasey PA, Paul J, et al (2005). Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. J Clin Oncol, 23, 8802. DOI |
7 | de Graeff P, Crijns AP, Ten Hoor KA, et al (2008). The ErbB signalling pathway; protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer, 99, 341-9. DOI |
8 | de Graeff P, Crijns AP, de Jong S, et al (2009). Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer, 101, 149-59. DOI |
9 | de Toledo MC, Sarian LO, Sallum LF, et al (2013). Analysis of the contribution of immunologically-detectable HER2, steroid receptors and of the “triple-negative” tumor status to disease-free and overall survival of women with epithelial ovarian cancer. Acta Histochem, 116, 440-7. |
10 | Gadducci A, Zola P, Landoni F, et al (1995). Serum half-life of CA125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study. Gynecol Oncol, 7, 42-7. |
11 | Hammond ME (2011). ASCO-CAP guidelines for breast predictive factor testing: an update. Appl Immunohistochem Mol Morphol, 19, 499-500. DOI |
12 | Han Y, Huang H, Xiao Z, et al (2012). Integrated analysis of gene expression profiles associated with response of platinum/ paclitaxel-based treatment in epithelial ovarian cancer. PLoS One, 7, 52745. DOI |
13 | Hogdall EV, Christensen L, Hogdall CK, et al (2007). Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from MALOVA ovarian cancer stuy. Oncol Rep, 18, 1051-9. |
14 | Lenhard M, Tereza L, Heublein S, et al (2012). Steroid hormone receptor expression in ovarian cancer: progesterone receptor B as prognostic marker for patients survival. BMC Cancer, 12, 553. DOI |
15 | Lassus H, Leminen A, Cheng G, et al (2004). ERBB2 amplification is superior to protein expression status in predicting patient outcome in serous ovarian carcinoma. Gynecol Oncol, 92, 31-9. DOI ScienceOn |
16 | Lassus H, Sihto H, Leminen A, et al (2006). Gene amplification, mutation, and protein expression of EGFR and mutations of ERBB2 in serous ovarian carcinoma. J Mol Med, 84, 671-81. DOI ScienceOn |
17 | Lee KR, Tavassoli FA, Prat J, et al (2003). Surface epithelialstromal tumours. In: Tavassoli FA, Devilee P editors. World Health Organization classification of tumours. pathology and genetics. tumours of the breast and female genital organs. Lyon. IARC Press, 117-45. |
18 | Liu N, Wang X, Sheng X (2010). The clinicopathological characteristics of triple-negative epithelial ovarian cancer. J Clin Pathol, 63, 240-3. DOI |
19 | Miller AB, Hoogstraten B, Staquet M, Winkler A (1981). Reporting results of cancer treatment. Cancer, 47, 207-14. DOI ScienceOn |
20 | Nielsen JS, Jakobsen E, Holund B, Bertelsen K, Jakobsen A (2004). Prognostic significance of p53, Her-2, and EGFR overexpression in borderline and epithelial ovarian cancer. Int J Gyn Cancer, 14, 1086-96. DOI |
21 | Noske A, Schwabe M, Weichert W, et al (2011). An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas. BMC Cancer, 11, 294. DOI |
22 | Siegel R, Ma J, Zou Z, Jemal A (2014) Cancer statistics, 2014. CA Cancer J Clin, 64, 9. DOI |
23 | Psyrri A, Kassar M, Yu Z, et al (2005). Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer. Clin Cancer Res, 11, 8637-43. DOI |
24 | Ray-Coquard I, Guastalla JP, Allouache D, et al (2009). HER2 Overexpression/amplification and trastuzumab treatment in advanced ovarian cancer: A GINECO Phase II Study. Clin Ovarian Cancer, 2, 17-22. DOI |
25 | Saxena R, Dwivedi A (2012). ErbB family receptor inhibitors as therapeutic agents in breast cancer: current status and future clinical perspective. Med Res Rev, 32, 166-215. DOI |
26 | Sinn BV, Darb-Esfahani S, Wirtz RM, et al (2011) Evaluation of a hormone receptor-positive ovarian carcinoma subtype with a favourable prognosis by determination of progesterone receptor and oestrogen receptor 1 mRNA expression in formalin-fixed paraffin-embedded tissue. Histopathol, 59, 918-27. DOI |
27 | Skirnisdottir I, Sorbe B, Seidal T (2001). The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma. Int J Gyn Cancer, 11, 119-29. DOI |
28 | Steffensen KD, Waldstrom M, Jeppesen U, et al (2007). The prognostic importance of cyclooxygenase 2 and HER2 expression in epithelial ovarian cancer. Int J Gynecol Cancer, 17, 798-807. DOI |
29 | Suprasert P, Chalapati W. Detection of recurrence in a surveillance program for epithelial ovarian cancer. Asian Pac J Cancer Prev, 14, 7193-6. 과학기술학회마을 DOI |
30 | Tuefferd M, Couturier J, Penault-Llorca F, et al (2007). HER2 status in ovarian carcinomas: a multicenter GINECO study of 320 patients. PLoS One, 2, 1138. DOI |
31 | Verri E, Guglielmini P, Puntoni M, et al (2005). HER1/ neu oncoprotein overexpression in epithelial ovarian cancer:evaluation of its prevalence and prognostic significance. Clinical study. Oncology, 68, 154-61. DOI |
32 | Winter WE 3rd, Maxwell GL, Tian C, et al (2007). Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol, 25, 3621. DOI |
33 | Yan B, Choo SN, Mulyadi P, et al (2011) Dual-colour HER2/ chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours. J Clin Pathol, 64, 1097-101. DOI |
34 | Yigit S, Demir L, Tarhan MO, et al (2012). The clinicopathological significance of Bax and Bcl-2 protein expression with tumor infiltrating lymphocytes in ovarian carcinoma. Neoplasma, 59, 475-85. DOI |
35 | Young RC, Decker DG, Wharton JT, et al (1983). Staging laparotomy in early ovarian cancer. JAMA, 250, 3072. DOI |
36 | Zhao D, Zhang F, Zhang W, et al (2013). Prognostic role of hormone receptors in ovarian cancer: a systematic review and meta-analysis. Int J Gyn Cancer, 23, 25-33. DOI |
37 | Ziolkowska-Seta I, Madry R, Kraszewska E, et al (2009). P53, BCL-2 and BAX analysis in 199 ovarian cancer patients treated with taxane-platinum regimens. Gynecol Oncol, 112, 179-84. DOI |
38 | Zivanovic O, Sima CS, Iasonos A, et al (2009). Exploratory analysis of serum CA-125 response to surgery and the risk of relapse in patients with FIGO stage IIIC ovarian cancer. Gynecol Oncol, 115, 209. DOI |